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Introduction
Schizophrenia and psoriasis are common complex disorders 
with large immune components.1,2 Schizophrenia has been 
shown to be associated with numerous autoimmune diseases, 
and psoriasis is a common immune-mediated inflammatory 
skin disease. Both result in a heavy societal and public health 
burden. Schizophrenia and psoriasis both have an estab-
lished genetic component,3,4 and are relatively common in the 
Han Chinese population (approximate prevalence of 1% and 
0.5%, respectively4,5). Cases of clinical comorbidity involving 
both schizophrenia and psoriasis have been reported.6 Epi-
demiological studies of the Taiwan Chinese population have 
shown that psoriasis develops in about 0.87% of patients with 
schizophrenia, which is a higher proportion than in the gen-
eral population.7,8 In addition, a study involving individuals 
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Background: Previous studies have shown that individuals with schizophrenia have a greater risk for psoriasis than a typical person. This 
suggests that there might be a shared genetic etiology between the 2 conditions. We aimed to characterize the potential shared genetic 
susceptibility between schizophrenia and psoriasis using genome-wide marker genotype data. Methods: We obtained genetic data on indi-
viduals with psoriasis, schizophrenia and control individuals. We applied a marker-based coheritability estimation procedure, polygenic 
score analysis, a gene set enrichment test and a least absolute shrinkage and selection operator regression model to estimate the potential 
shared genetic etiology between the 2 diseases. We validated the results in independent schizophrenia and psoriasis cohorts from Singapore. 
Results: We included 1139 individuals with psoriasis, 744 with schizophrenia and 1678 controls in our analysis, and we validated the results 
in independent cohorts, including 441 individuals with psoriasis (and 2420 controls) and 1630 with schizophrenia (and 1860 controls). We 
estimated that a large fraction of schizophrenia and psoriasis risk could be attributed to common variants (h2SNP = 29% ± 5.0%, p = 2.00 × 10–8), 
with a coheritability estimate between the traits of 21%. We identified 5 variants within the human leukocyte antigen (HLA) gene region, 
which were most likely to be associated with both diseases and collectively conferred a significant risk effect (odds ratio of highest risk quartile = 
6.03, p < 2.00 × 10–16). We discovered that variants contributing most to the shared heritable component between psoriasis and schizophrenia 
were enriched in antigen processing and cell endoplasmic reticulum. Limitations: Our sample size was relatively small. The findings of 5 HLA 
gene variants were complicated by the complex structure in the HLA region. Conclusion: We found evidence for a shared genetic etiology 
between schizophrenia and psoriasis. The mechanism for this shared genetic basis likely involves immune and calcium signalling pathways.
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in the Danish nationwide registry suggests that the incidence 
of psoriasis is nearly twice as high in patients with schizo-
phrenia than the general population. Moreover, they found 
that the incidence of autoimmune disorders in patients with 
schizophrenia or individuals with a family history of schizo-
phrenia is increased. It is estimated that autoimmune diseases 
develop in about 3.6% of individuals with schizophrenia and 
that about 3.1% of people with autoimmune diseases have a 
family history of schizophrenia.9,10 In light of these findings, it 
is quite likely that comorbidity of schizophrenia and psoriasis 
arises as a result of a shared autoimmune dysfunction.1,2,11
Previous results from our genome-wide association studies 
(GWAS) conducted independently in Han Chinese schizo-
phrenia and psoriasis cohorts suggested that a shared suscep-
tibility to these disorders may stem from genetic variants on 
chromosome 6, as it was found to be associated with both dis-
orders. It is noteworthy that the human leukocyte antigen 
(HLA) gene has been implicated in many immune disorders.3,4 
In addition, other researchers have identified variants in the 
CSMD1 gene as a contributing factor to both diseases.12,13 
However, to our knowledge, no studies published to date 
have comprehensively explored the potential common genetic 
etiology of schizophrenia and psoriasis.
In order to avoid false-positive findings in GWAS, a strin-
gent significance threshold is usually applied. When sample 
sizes are small, conventional GWAS of complex diseases may 
overlook variants with small or moderate effects. Several 
complementary approaches have been developed to improve 
the characterization of the genetic basis of common disorders 
and traits in GWAS settings (e.g., gene-based association tests, 
gene-set analyses).14,15 In addition, it is now recognized that 
many common disorders and traits have a polygenic basis 
(i.e., many genes, each with a small effect, contribute to a 
phenotype) that can be characterized through the use of 
whole genome genotype data. In fact, the genetic architecture 
for many common diseases and complex traits has been char-
acterized through polygenic methods.16–18 Given that most 
common disorders and traits have been shown to have a 
polygenic basis, many researchers have explored the possi-
bility that many complex disorders and traits, including 
schizophrenia and psoriasis, actually share genetic deter-
minants (i.e., are genetically correlated to some degree).19–26 
This trend appears to be even more pronounced in diseases 
of autoimmune origin.27 In this light, we tested our hypothesis 
of a shared genetic basis of schizophrenia and psoriasis using 
large cohorts previously studied in independent GWAS.
Methods
Study design, samples and quality control
We pursued our analyses in 3 stages. In stage 1, we used the 
mixed linear model to explore the polygenic architecture of 
schizophrenia and psoriasis in isolation and then combined the 
data associated with each and reran the analysis. In stage 2 we 
used 2 popular methods to quantify the possible genetic cor-
relation between schizophrenia and psoriasis: bivariate mixed 
linear modelling, as implemented in the genome-wide complex 
trait analysis (GCTA) software suite, and polygenic scoring 
profile using standard methods. Finally, in stage 3 we used 
standard single variant association tests to identify candidate 
variants that might be associated with both conditions in a 
more pronounced way than others, and we looked for common 
molecular pathways affected by the most strongly associated 
variants using gene-set enrichment analyses. This 3-stage strat-
egy is summarized in Appendix 1, Fig. S1, available at jpn.ca.
Two previously reported independent schizophrenia and 
psoriasis cohorts of Han Chinese descent were used in the 
present study.3,4 The schizophrenia diagnosis was made by at 
least 2 experienced psychiatrists according to DSM-IV criteria. 
No participants had severe medical complications or other 
psychiatric disorders. The clinical diagnosis of psoriasis was 
also confirmed by at least 2 dermatologists. To enrich for indi-
viduals with a likely overt genetic basis for their condition, we 
preferentially selected individuals with type 1 psoriasis (early 
age of onset) who had a family history of disease. All control 
individuals were clinically determined to be free of autoim-
mune or psychiatric disorders, psoriasis or family history of 
such disorders (including first-, second- and third-degree rela-
tives). We collected additional clinical and demographic infor-
mation on all cohorts through questionnaires. Individuals 
were categorized into 3 groups based on disease status: a psor-
iasis case–control cohort, a schizophrenia case–control cohort 
and a combined cohort (i.e., all individuals from both studies). 
There were no individuals common to both the schizophrenia 
and psoriasis cohorts. It should be noted that we did not make 
the diagnosis and exclusion of schizophrenia in the psoriasis 
cohort, and vice versa. All participants provided written in-
formed consent. This study was approved by the institutional 
review boards of The First Affiliated Hospital, Anhui Medical 
University and Institute of Mental Health, Peking University.
Genotyping was performed on the Illumina Human 610-
Quad BeadChip according to the manufacturer’s specifications. 
We applied quality control procedures, resulting in the exclu-
sion of markers with a minor allele frequency (MAF) less than 
0.01, call rate less than 0.9, deviation from Hardy–Weinberg 
equilibrium in the controls (p < 1 × 10–6), all markers on the X, Y 
and mitochondrial chromosomes and the copy number variant 
(CNV)–related probes. Individuals with low overall call rates 
(<  0.9) were excluded from the study. We performed 
 genome-wide genotype imputation on autosomal chromo-
somes using IMPUTE2 software and the 1000 Genomes Pro ject 
phase 1 integrated variant set reference panel.28 Imputed calls 
were made using a threshold of 0.9 in the software GTOOL 
(www.well.ox.ac.uk/~cfreeman /software /gwas/gtool.html). 
Markers with info values less than 0.5 were excluded. Imputed 
markers were also subject to the quality control procedures 
 implemented on the genotyped data described above.
Estimation of the phenotypic variation explained by 
 polygenic factors
We computed genetic relatedness matrices (GRM) in each of 
the 3 cohorts (schizophrenia, psoriasis, combined) from geno-
typed and imputed autosomal markers using the GCTA soft-
ware.16 We excluded 1 individual from each pair of related 
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individuals (relatedness < 0.025). This resulted in the exclu-
sion of 11, 14, and 67 individuals in the psoriasis, schizophre-
nia and combined cohorts, respectively. Restricted maximum 
likelihood (REML) estimation was applied to estimate the 
proportion of variation explained in the liability of a disease 
by genetic markers (h2SNP) in each of the cohorts. To facilitate 
the analyses, we set the prevalence of psoriasis, schizophre-
nia, and the combined cohort to 0.47%, 1%, and 1.47%, respec-
tively, based on published data.5,29 We included the first 
20 principal components from the GRM as covariates in the 
analyses to accommodate genetic background heterogeneity 
and potential stratification. The contribution of genetic mark-
ers to disease status in each of the cohorts was further broken 
down into components based on chromosome and MAF. In 
the former case, genetic markers were partitioned into groups 
based on chromosome. We estimated GRMs for each chromo-
some, and the proportion of disease liability explained by 
each chromosome was calculated independently (separate 
analysis) as well as jointly with all other chromosomes (joint 
analysis). Likewise, genetic markers were partitioned based 
on MAF (uncommon: 0.01 < MAF < 0.05; common: MAF > 
0.05), and independent and joint analyses were performed.30 
We conducted an REML analysis using the GCTA package to 
characterize the polygenic architecture of schizophrenia, psor-
iasis and the combined phenotype.16 To quantify the genetic 
correlation (or coheritability) between schizophrenia and 
psor iasis, we implemented a bivariate extension of the REML 
methods in the GCTA software with the combined cohort.31
Polygenic scoring profile
The shared contribution of genetic variants including, but not 
limited to, the HLA region, was assessed using markers geno-
typed in both the schizophrenia and psoriasis cohorts. Markers 
were pruned based on linkage disequilibrium (LD) with neigh-
bouring markers (maximum threshold for pairwise r2 of 0.25, 
200–single nucleotide polymorphism [SNP] window). We then 
treated the schizophrenia data set as the discovery (i.e., training) 
set and the psoriasis data set as the target (i.e., test) set, and vice 
versa. Based on the association statistics in the training set, we 
selected 5 sets of markers  using various significance thresholds 
(pT; markers with pT < 0.001, pT < 0.05, pT  < 0.1, pT < 0.5 as well as 
all markers). In the target set, we calculated genetic risk scores 
for each individual as the sum of the risk alleles weighted by the 
corresponding natural log of odds ratios estimated in the dis-
covery set. The scoring was implemented in the PLINK tool set 
via the score function.32 A logistic regression model was then fit 
 using the estimated genetic risk score as the independent vari-
able and disease as the dependent variable. We calculated the 
area under the receiver operating characteristic (ROC) curve 
(AUC) to assess the degree to which schizophrenia risk esti-
mates predicted susceptibility to psoriasis and vice versa.
Genome-wide association analysis and modelling in the 
HLA region
Single variant association analyses were pursued assuming 
the additive allelic model as implemented in the PLINK 1.07 
software suite for each of the 3 cohorts.32 The first 20 principal 
components extracted from a GRM across all individuals in a 
study were included as covariates to account for possible 
gen etic stratification in the sample. After LD-based pruning, 
markers in the HLA region that exhibited a pronounced asso-
ciation with disease in the combined cohort (p < 1 × 10–5) 
showed nominal association with both the schizophrenia and 
psoriasis cohort (p < 0.05), and displayed the same direction 
of effect and were therefore included in specific additional 
analyses (referred to as “marker subset A”).
All 680 genotyped and imputed markers in the HLA region 
were considered in a least absolute shrinkage and selection 
operator (LASSO) logistic regression model in the combined 
cohort via the glmnet analysis package in R software version 
3.0.33 We performed 10-fold cross-validation to select the 
value of the tuning parameter λ, which maximized the AUC 
(Appendix 1, Fig. S2). Markers with nonzero effect estimates 
from the LASSO model were noted (referred to as “marker 
subset B”). Twelve markers were common in both marker 
subsets A and B. These markers were then fit in a stepwise lo-
gistic regression model in the combined cohort, and param-
eter estimates and corresponding conditional association sta-
tistics were recorded. The results of this analysis suggested 
that 7 of the 12 markers were not associated with disease 
when the effects of the other markers were considered in a 
single all- encompassing model. Using the remaining 5 in-
dependently associated markers, we calculated a genetic risk 
score for each individual in the combined cohort using a 
weighted allele counting approach29 in which weights were 
assigned based on the effect size estimates obtained from the 
logistic regression model. Bins were constructed based on the 
risk score quartiles among controls, and odds ratios in each 
bin were calculated with respect to the first quartile.
Functional annotation and gene ontology
The functional effects of the 12 HLA markers identified above 
as well as the non-HLA markers with suggestive significance 
in the combined cohort (p < 1 × 10–5; n = 12 markers) were in-
vestigated with information from the ENCODE database 
 using HaploReg.34 The overlap in shared biological processes 
between psoriasis and schizophrenia was explored using gene 
set enrichment analysis (GSEA) implemented in the Aligator 
software package.15 We performed the GSEA analyses in the 
schizophrenia, psoriasis and combined cohorts individually. 
Only markers exceeding a single SNP association threshold 
(p < 0.001) in their respective data sets were  included.
Independent validation
Findings were validated from the summary statistics of 
2  GWAS in schizophrenia35 (1630 cases and 1860 controls) 
and psoriasis36 (441 cases and 2420 controls) of Singapore 
Chinese descent. The schizophrenia data set came from the 
Singapore Translational and Clinical Research in Psychosis 
(STCRP) Study. All patients were recruited from the Insti-
tute of Mental Health in Singapore from 2005 to 2008 and 
were aged 18–83 years. The diagnosis of schizophrenia was 
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made using the Structured Clinical Interview for DSM-IV, 
Research Version, Patient Edition (SCID-I/P). The controls 
were from the Singapore Prospective Study Program 11, 
who were randomly sampled from the Singapore popula-
tion. All these samples were genotyped by Illumina 1M 
duo3 array. The Singapore psoriasis cohort included indi-
viduals who were genotyped using the Illumina Human550 
BeadChip, whereas the controls were genotyped using Illu-
mina Human550, Illumina Human610 Quad and 1M duo3 
BeadChip. There was no overlap between the schizophrenia 
and psoriasis validation cohorts. Genetic variant imputation 
was performed individually in each study using the 1000 
Genomes Project reference panel, and unified quality con-
trols (impute INFO > 0.8, MAF > 0.01, Hardy–Weinberg 
equilibrium test p > 1.00 × 10–5 in controls, dosage threshold 
> 0.9, call rate > 0.99), and LD-pruning criteria (SNPs pruned 
by  indep-pairwise 50 5 0.3 parameter in PLINK 1.07) were 
applied. We considered only biallelic markers in the analy-
ses. The probabilistic significance of variants exhibiting con-
sistent direction of effect between the validation studies was 
assessed using a binomial test, assessing Pr(X > x), where 
X~bin(n,p), n = the number of markers reaching a particular 
significance level in both studies, p = 0.5, and x = the number 
of markers at the corresponding significance level with the 
same direction of effect.
Results
Population
Individuals were categorized into 3 groups based on disease 
status: a psoriasis case–control cohort (1139 cases and 
1132 controls), a schizophrenia case–control cohort (744 cases 
and 546 controls) and a combined cohort (1883 cases and 
1678 controls). There was no overlap between the schizophre-
nia and psoriasis cohorts. We excluded 79 individuals with 
low overall call rates (< 0.9) from our analysis.
Summary description
After genomic imputation and quality control, we obtained 
genetic data on roughly 5.6 million high-quality autosomal 
SNPs in the schizophrenia, psoriasis and combined cohorts. 
Inspection of the single marker association results in the 
combined cohort revealed no obvious bias or population 
stratification issues (genomic inflation factor λGC = 1.01; Ap-
pendix 1, Fig. S3). The quantile-quantile (QQ) plot and 
Manhattan plot in the combined cohort are shown in Ap-
pendix 1 (Fig. S4 and Fig. S5). At the upper tail of the distri-
bution, the QQ plot showed an obvious deviation from the 
null distribution owing to the effects of the HLA region. 
Thus, after omitting SNPs in this region (chr.6: 29 700 kb- 
33 300 kb), the distribution of observed p values largely fit 
the null (i.e., uniform) distribution. In view of evidence of a 
shared common polygenic contribution, the deviation in the 
QQ plot after omitting SNPs in the HLA region potentially 
shows the aggregate effects of a moderate number of low-
risk variants.
Proportion of liability explained by common variants in 
schizophrenia and psoriasis
We discovered that 41.3% ± 13.9% (p = 0.002) of the variation in 
genetic liability for schizophrenia was captured by genotyped 
and imputed variants. The proportion of liability explained by 
markers on each chromosome was linearly correlated with the 
length of the respective chromosome (R2 = 0.1, p = 0.09; Fig. 1 
and Appendix 1, Fig. S6). A partition of markers based on MAF 
(common: MAF > 0.05; uncommon: 0.01 < MAF < 0.05) sug-
gested that common variants were the main contributors to the 
polygenic liability (> 85%; Appendix 1, Fig. S7 and Table S1). 
Meanwhile, we found that 34.9% ± 6.0% (p = 9.0 × 10–9) of the 
variation in genetic liability for psoriasis was captured by geno-
typed and imputed variants.37 We observed that chromosome 6 
was the main contributor to SNP heritability (h2SNP) in both the 
schizophrenia and psoriasis cohorts (Fig. 1 and Appendix 1, 
Fig. S6). Furthermore, the genetic variance explained by each 
chromosome was highly correlated between schizophrenia and 
psoriasis (R2 = 0.93, p = 0.005).
Coheritability and shared genetic etiology of schizophrenia 
and psoriasis
We next evaluated SNP heritability in the combined cohort 
(n = 3494). We found that 29.4% ± 5.0% (p = 2.0 × 10–8; Ap-
pendix 1, Table S2) of the genetic liability for disease was 
captured by genotyped and imputed markers. We assessed 
genome-wide pleiotropy between schizophrenia and psoria-
sis using marker-based coheritability (Appendix 1, Table S3). 
We estimated the coheritability (rg SNP) as 0.21 ± 0.20, (p = 
0.10). This finding provides preliminary evidence that 
schizophrenia and psoriasis possibly share a common gen-
etic etiology. Our analysis of each chromosome individually 
suggested that the coheritability was distributed roughly 
equally across chromosomes, suggesting in turn that a 
shared pattern of polygenic contribution to disease exists 
(Appendix 1, Table S4).
Encouraged by previous results from GWAS initiatives in 
schizophrenia and psoriasis that have shown susceptibility 
variants in the HLA region (as well as our discoveries on 
chromosome 6), we extracted all 49 332 SNPs in an extended 
HLA region (chr.6: 25–34 MB) and found that 7.0% ± 1.0% (p < 
1 × 10–8) of genetic liability for disease was captured by the 
HLA variants in the combined cohort (Appendix 1, Table S5). 
We then estimated the contribution of each individual chro-
mosome to h2SNP in the combined cohort. We again found that 
the variance in disease liability explained by each chromo-
some was linearly correlated with its length when chromo-
somes were considered independently (R2 = 0.42, p = 0.001) 
after omitting chromosome 6 owing to its substantial contri-
bution (Fig. 1). However, the correlation was considerably 
smaller when examining the contribution of each chromo-
some, conditional on the others (R2 = 0.10, p = 0.09; Appendix 
1, Fig. S6).  Finally, we again partitioned markers into 2 cate-
gories based on MAF. We found that roughly 80% of the esti-
mated heritability of disease was due to common variants 
(Appendix 1, Fig. S7 and Table S6).
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Polygenic scoring profile analysis
After pruning based on LD, we identified 222 161 independ-
ent SNPs genotyped in both the schizophrenia and psoriasis 
cohorts. We constructed a polygenic risk score using data 
from the schizophrenia cohort and tested this model in the 
psoriasis cohort (and vice versa) using 5 different p value 
thresholds. We discovered that genetic risk in 1 cohort was a 
significant predictor of genetic risk in the alternative cohort 
(Table 1). Interestingly, the AUC was highest when using 
more moderate significance thresholds in the discovery set, 
implying that genetic background and/or variants with 
small effects may contribute to the shared etiology between 
schizophrenia and psoriasis.
Association analysis and modelling in the HLA region
After LD pruning, we identified 565 SNPs with nominal asso-
ciation (p < 0.05) in both the schizophrenia and psoriasis co-
horts. More of these markers (55%) displayed the same direc-
tion of effect that would be expected by chance (binomial test 
p = 0.02). Many of these markers (n = 22) were found in the 
HLA region and showed some evidence for association (p < 
1 × 10–5) in the combined cohort (subset A). We then mod-
elled all 680 markers in the HLA region with nominal signifi-
cance (p < 0.05) in the schizophrenia, psoriasis and combined 
cohorts simultaneously using a LASSO penalized regression 
model. Markers with nonzero regression coefficients were re-
corded (subset B). Twelve markers reached our criteria for 
subset A and subset B (Table 2, Appendix 2, Table S9 and 
S10). Among those, we performed forward and backward 
stepwise regression and discovered 5 SNPs that jointly con-
tributed to disease risk in the combined cohort (Appendix 1, 
Fig. S8 and Appendix 2, Table S9 and S10). In construction of 
a genetic risk score based on these 5 markers, we found that 
the highest-risk group was 6 times more likely than the 
 lowest-risk group to have disease (p < 2.00 × 10–16; Fig. 2).
Gene ontology analysis
To explore potential shared biological processes between 
schizophrenia and psoriasis, we implemented gene ontology 
analyses in the combined, schizophrenia and psoriasis co-
horts separately. We found 18 categories showing significant 
enrichment in each of the 3 data sets (Appendix 2, Table S8). 
Most were involved in antigen process and presentation and 
in endoplasmic reticulum.
Independent validation in the Singapore Chinese population
After genomic imputation and LD pruning, we found that 
68  922 SNPs from approximately 6 million genotyped and 
imputed bi- allelic markers were shared in the Singapore 
schizophrenia and psoriasis data sets. We used these SNPs 
to assess the consistency of the p values for association be-
tween schizophrenia and psoriasis. Markers were placed 
into bins based on their significance level obtained in both 
data sets: p ≤ 0.01, 0.03, 0.05, 0.07, 0.08, 0.09 and 0.10. Then the 
number of markers with the same direction of effect in each 
bin was enumerated, and the consistency of directional effect 
Fig. 1: The distribution of genetic variance explained by each autosomal chromosome in a joint analysis in 3 cohorts. 
The X axis denotes the length proportion of each individual chromosome in the whole genome. The Y axis denotes 
the proportion of total genetic variation. The results in the schizophrenia, psoriasis and combined cohorts are depicted 
in red triangles, brown squares and blue circles, respectively. The numbers in the circles/squares/triangles are 
the chromosome numbers. The linear correlation between the chromosome length proportion and the proportion of 
total genetic variation is described using 3 equations in different colors (red: schizophrenia; orange: psoriasis; blue: 
combined phenotype).
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was evaluated using a binomial test (Appendix 1, Table 
S11). The results suggest that there are indeed genetic vari-
ants that exhibit pleiotropic effect in the sense that they are 
associated with the risk for both schizophrenia and psoria-
sis, although the pleiotropic effect of any single variant may 
be small. In addition, although the independent validation 
data sets didn’t provide direct validation to our findings in 
the HLA region, single locus analyses of these independent 
validation data sets, suggested that several SNPs residing in 
the HLA region conferred significant risk for both schizo-
phrenia and psoriasis, and the effect of the deleterious SNP 
allele was in the same direction in both conditions, adding 
further evidence to our initial findings involving the HLA 
region (Appendix 1,Table S12).
Discussion
Main findings and implications
In the present study, we characterized the polygenic architec-
ture of schizophrenia and psoriasis and explored the possi-
bility of shared genetic etiology between schizophrenia and 
psoriasis in the Han Chinese population. Our study provides 
preliminary evidence to support the polygenic basis of both 
diseases. We found evidence that a shared genetic etiology 
(i.e., genetic correlation) exists between schizophrenia and 
psor iasis, and we were able to quantify, to our knowledge for 
the first time, the strength of the genetic correlation (or coherit-
ability) through the use of whole genome genotype array data. 
In particular, the contribution of the HLA region appears to be 
shared between diseases, and we identified 5 SNPs residing in 
the HLA region contributing in a more pronounced way than 
other variants to the risk of both diseases. These results high-
light the potentially important role of antigen presentation and 
endoplasmic reticulum pathways in the genetically mediated 
etiology of schizophrenia and psoriasis.
Ultimately, we explored the polygenic architecture of 
schizophrenia and psoriasis in the Han Chinese samples. The 
finding verified the polygenic characteristics of schizophrenia 
in our samples.30 In addition, our results highlight the impor-
tant role of common variants in the etiology of both schizo-
phrenia and psoriasis. In general, it appears that both dis-
eases follow a polygenic model of inheritance30,37 (i.e., beyond 
the HLA region), predominantly influenced by common vari-
ants with small effects. It has been shown that 23% of the 
variation in genetic liability for schizophrenia is captured by 
common variants in the European population.30 The differ-
ence between our estimate of variation in liability for schizo-
phrenia (41.3%) and liability in European samples is possibly 
owing to sampling error given the different sample sizes 
used in the studies. Furthermore, we tested the hypothesis of 
a shared genetic etiology for schizophrenia and psoriasis 
 using single-marker, multimarker and gene ontology analy-
ses with 2 independent Han Chinese GWAS cohorts. We 
identified evidence of genetic correlation or coheritability be-
tween schizophrenia and psoriasis across several analytical 
approaches. Moreover, our independent validation in the 
Singapore Chinese provided complementary evidence of this 
common genetic etiology. Recently, evidence has been found 
for genetic pleiotropy between many complex human dis-
eases, especially immune-mediated disorders.19,21,22,24–26,29 
Schizophrenia has been shown to share a common genetic 
basis not only with other psychiatric diseases (e.g.. bipolar 
disorder), but also with metabolic (e.g., type 2 diabetes) and 
Table 1: The results of polygenic scoring profile analysis
Target pT value* No. SNPs† AUC (95% CI) pAUC value
Schizophrenia < 0.001 189 0.52 (0.48–0.55) 0.16
Schizophrenia < 0.05 10 616 0.53 (0.50–0.56) 0.036
Schizophrenia < 0.1 21 685 0.54 (0.51–0.58) 0.004
Schizophrenia < 0.5 110 329 0.53 (0.50–0.56) 0.042
Schizophrenia ≤ 0.99 222 161 0.53 (0.50–0.56) 0.032
Psoriasis < 0.001 182 0.51 (0.48–0.53) 0.25
Psoriasis < 0.05 11 376 0.53 (0.51–0.56) 0.004
Psoriasis < 0.1 22 927 0.54 (0.52–0.56) < 0.001
Psoriasis < 0.5 112 645 0.54 (0.52–0.57) < 0.001
Psoriasis ≤ 0.99 222 161 0.54 (0.51–0.56) 0.002
AUC = area under the receiver operating characteristics curve; CI = confidence 
interval; SNP = single nucleotide polymorphism.
*Threshold of association p value in the discovery set. 
†Number of SNPs with a p value in the discovery set. 
Fig. 2: The combined risk effect distribution of 5 single nucleotide 
polymorphisms (SNPs) in the human leukocyte antigen (HLA) region 
in the combined cohort. The X axis denotes the genetic risk score 
group. The left Y axis denotes the number of individuals in each group. 
The right Y axis represents the odds ratio. Group 0 = the genetic risk 
score is less than the 25% quartile of that in controls. Group 1 = the in-
dividual score is less than the median but larger than the 25% quartile 
in controls. Group 2 = the genetic risk score is larger than the median 
but less than the 75% quartile of that in controls. Group 3 = the score 
is larger than the 75% quartile of that in controls. Odds ratios were cal-
culated with respect to Group 0. The number of controls and cases are 
in orange and blue, respectively.
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immune disorders (e.g., rheumatoid 
arthritis).19,25,26 We estimated that 21% 
of the genomic contribution to both 
schizophrenia and psoriasis could be 
attributed to the shared genetic vari-
ants. This finding was validated using 
a polygenic scoring profile analysis 
and replicated in our independent 
Singa pore data sets. Clinical cases of 
individuals with both schizophrenia 
and psoriasis have been documented.6 
Large epidemiological studies have 
shown that the higher incidence of 
psoriasis in patients with schizophre-
nia and even in individuals with a 
family history of schizophrenia in both 
Chinese and European popula-
tions.7–10,20 While we demonstrated a 
shared genetic etiology between these 
diseases, common environmental fac-
tors may still play a role in the disease 
coetiologies (e.g., stress event in epi-
demiological studies).38,39 The addi-
tional role of environmental factors 
and how such environmental factors 
may influence genetic factors (i.e., gene 
× environment interactions) remains to 
be explored. As we used  genome-wide 
genotype array data, we could at least 
argue that our study is not likely to be 
attributable to shared environmental 
factors because it is highly unlikely 
that environmental stressors or stimuli 
correlate perfectly with, for example, a 
genome-wide risk score for each disor-
der. In addition, our result demon-
strating coheritability and consistent 
effective direction of common variants 
between schizophrenia and psoriasis 
agrees with clinical observation and 
prior epidemiological evidence. Ulti-
mately, we argue that the common 
gen etic etiology would account for the 
comorbidity of schizophrenia and 
psor iasis in proportion. However, con-
sidering the relatively moderate sam-
ple size of our study, further efforts to 
more accurately estimate coheritability 
should be explored.
It is strongly believed that the im-
mune process plays an important role 
in schizophrenia and psoriasis.2,3,11 Re-
cent studies provide evidence that sus-
ceptibility to both diseases can be attrib-
uted to the HLA variants.1,3,4,29,40 In this 
study, we highlighted the important 
role of chromosome 6, and investigated 
markers residing in the HLA region. By T
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modelling markers in this region, we identified 5 SNPs that 
jointly contribute to disease susceptibility. Our results confirm 
earlier reports that suggest the HLA region is involved in 
schizophrenia and psoriasis1,3,4,29,40 and shed light on their 
polygenic architecture. The 5 SNPs we assessed in the HLA 
region that jointly contribute to disease may contribute to the 
etiology of schizophrenia and psoriasis through a regulatory 
effect (Appendix 1, Table S9). The markers we identified im-
plicate HLA-B, HLA-C, MICB and HLA-DRB as joint contribu-
tors to disease susceptibility. Notably, 1 of these markers 
(rs41293883) is a missense polymorphism in the MICB gene 
that results in amino acid change from threonine to isoleucine, 
although it is predicted to be benign in Polyphen2. We did not 
impute the HLA molecules or amino acid status.  Owing to the 
complexity of the HLA region and the need for more focused 
analysis involving the HLA region, future  studies are needed.
Beyond the antigen presentation processing pathways, we 
found evidence that several biological pathways related to 
the endoplasmic reticulum harbour variants that are shared 
between schizophrenia and psoriasis. The endoplasmic reticu-
lum plays an important role in the transportation of calcium 
ion in cells.41 Our findings therefore provide some level of vali-
dation of the potential role of calcium signalling in the etiology 
of schizophrenia and psoriasis.13,42,43
Strengths and limitations
The strength of our study is rooted in the use of multiple 
complementary statistical approaches designed to identify 
genetic correlations that all suggest a shared genetic etiology 
between schizophrenia and psoriasis. We were able to quan-
tify the genetic correlation (coheritability) between schizo-
phrenia and psoriasis through genome-wide array data, and 
to our knowledge this had not been shown before. In addi-
tion, we were able to replicate our results in an independent 
Singapore Chinese population. 
Our study’s limitations revolve around our relatively 
small samples, which led to a standard error on our estimates 
of genetic correlation and coheritability from the bivariate 
linear mixed model. In addition, the AUC value obtained 
from our polygenic scoring profile analyses is not very large. 
Larger studies should be pursued to replicate and validate 
our findings. Based on previous findings suggesting that 
variants in the HLA region are most likely to be associated 
with both diseases,3,29 we tested the hypothesis that specific 
variants in the HLA region could predispose to both diseases. 
We found credible evidence for this phenomenon. However, 
the complex LD structure among variants in the HLA region 
complicates the prioritization of specific variants, and as 
such our finding that 5 HLA variants exhibit associations 
warrants validation in independent samples. In addition, the 
precise molecular mechanism underlying these association 
signals remains to be elucidated.
Conclusion
We identified a polygenic contribution to schizophrenia and 
psoriasis in the Han Chinese population. We discovered a 
shared genetic etiology between the disorders, a large frac-
tion of which could be accounted for mainly by common 
variants, particularly in the HLA region. The mechanism for 
this shared genetic basis seems to involve immune and 
calcium -signalling pathways.
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